Literature DB >> 10471062

Human nicotinamide N-methyltransferase pharmacogenetics: gene sequence analysis and promoter characterization.

L Yan1, D M Otterness, R M Weinshilboum.   

Abstract

Nicotinamide N-methyltransferase (NNMT) catalyses the N-methylation of nicotinamide and structurally related pyridines. NNMT enzymatic activity in human liver varies over a five-fold range with a bimodal frequency distribution - raising the possibility of regulation by a genetic polymorphism. We set out to characterize molecular genetic mechanisms that might be involved in the regulation of individual variation in human liver NNMT activity. After Northern blot analysis confirmed that NNMT is highly expressed in the liver, eight human hepatic biopsy samples, four each with 'low' or 'high' levels of activity, were used to perform quantitative Western blot analysis. There was a highly significant correlation (r(s) = 0.96, P < 0.0001) between NNMT activity and immunoreactive protein in these samples. We next determined that a potent promoter was located within the initial 700 bp of the 5'-flanking region of the human NNMT gene. That gene consists of 3 exons, with an initial 1240 bp intron and a second intron that is approximately 14 kb in length. We subsequently isolated DNA from 27 human liver biopsy samples with low, intermediate or high levels of NNMT activity. The three exons, all 1240 bp of intron 1 and approximately 700 bp of the 5'-flanking region of the NNMT gene were amplified from each of these samples with the polymerase chain reaction, followed by DNA sequencing to identify genetic polymorphisms that might correlate with 'NNMT phenotype'. No single nucleotide polymorphisms (SNPs) or insertion/deletion events were detected within either the exons or 5'-flanking regions of NNMT for these 27 samples. Although there were eight SNPs within intron 1, none were systematically related to level of NNMT activity. These results indicate that the exons and 5'-flanking region of the NNMT gene display little or no sequence variation. Therefore, polymorphisms within these areas of the gene are unlikely to be related to wide individual variations in the level of this enzyme activity in the human liver.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10471062     DOI: 10.1097/00008571-199906000-00005

Source DB:  PubMed          Journal:  Pharmacogenetics        ISSN: 0960-314X


  12 in total

Review 1.  Pharmacogenomics: catechol O-methyltransferase to thiopurine S-methyltransferase.

Authors:  Richard M Weinshilboum
Journal:  Cell Mol Neurobiol       Date:  2006-06-29       Impact factor: 5.046

2.  Toxic effects of nicotinamide methylation on mouse brain striatum neuronal cells and its relation to manganese.

Authors:  Yayoi Mori; Akiko Sugawara; Masayoshi Tsuji; Takeyasu Kakamu; Satoshi Tsuboi; Hideyuki Kanda; Takehito Hayakawa; Tetsuhito Fukushima
Journal:  Environ Health Prev Med       Date:  2012-01-15       Impact factor: 3.674

3.  A genomewide exploration suggests a new candidate gene at chromosome 11q23 as the major determinant of plasma homocysteine levels: results from the GAIT project.

Authors:  Juan Carlos Souto; Francisco Blanco-Vaca; José Manuel Soria; Alfonso Buil; Laura Almasy; Jordi Ordoñez-Llanos; Jesús Ma Martín-Campos; Mark Lathrop; William Stone; John Blangero; Jordi Fontcuberta
Journal:  Am J Hum Genet       Date:  2005-04-22       Impact factor: 11.025

Review 4.  Insights into S-adenosyl-l-methionine (SAM)-dependent methyltransferase related diseases and genetic polymorphisms.

Authors:  Jiaojiao Li; Chunxiao Sun; Wenwen Cai; Jing Li; Barry P Rosen; Jian Chen
Journal:  Mutat Res Rev Mutat Res       Date:  2021-10-07       Impact factor: 7.015

5.  Stat3 up-regulates expression of nicotinamide N-methyltransferase in human cancer cells.

Authors:  Mikio Tomida; Hideki Ohtake; Takashi Yokota; Yasuhito Kobayashi; Masafumi Kurosumi
Journal:  J Cancer Res Clin Oncol       Date:  2007-10-06       Impact factor: 4.553

6.  Development of oxidative stress by cytochrome P450 induction in rodents is selective for barbiturates and related to loss of pyridine nucleotide-dependent protective systems.

Authors:  Miroslav Dostalek; Klarissa D Hardy; Ginger L Milne; Jason D Morrow; Chi Chen; Frank J Gonzalez; Jun Gu; Xinxin Ding; Delinda A Johnson; Jeffrey A Johnson; Martha V Martin; F Peter Guengerich
Journal:  J Biol Chem       Date:  2008-04-28       Impact factor: 5.157

7.  1-Methylnicotinamide (MNA), a primary metabolite of nicotinamide, exerts anti-thrombotic activity mediated by a cyclooxygenase-2/prostacyclin pathway.

Authors:  S Chlopicki; J Swies; A Mogielnicki; W Buczko; M Bartus; M Lomnicka; J Adamus; J Gebicki
Journal:  Br J Pharmacol       Date:  2007-07-16       Impact factor: 8.739

8.  Serum levels of nicotinamide N-methyltransferase in patients with lung cancer.

Authors:  Mikio Tomida; Iwao Mikami; Shingo Takeuchi; Hitoshi Nishimura; Hirohiko Akiyama
Journal:  J Cancer Res Clin Oncol       Date:  2009-02-26       Impact factor: 4.553

9.  Nicotinamide N-methyltransferase protein expression in renal cell cancer.

Authors:  Jun Zhang; Xin-you Xie; Su-wen Yang; Jin Wang; Chao He
Journal:  J Zhejiang Univ Sci B       Date:  2010-02       Impact factor: 3.066

Review 10.  Possible Adverse Effects of High-Dose Nicotinamide: Mechanisms and Safety Assessment.

Authors:  Eun Seong Hwang; Seon Beom Song
Journal:  Biomolecules       Date:  2020-04-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.